Management of Elevated INR and Vitamin K Administration

Moderate INR Elevation (INR 4.5–10) – No Bleeding

• Routine vitamin K is not recommended (Grade 2B); pooled randomized trials showed no reduction in major bleeding (2 % with vitamin K vs 0.8 % with placebo) or thromboembolism. 1
• Withhold warfarin for 1–2 doses and re‑measure INR after 24–48 h. 3

Severe INR Elevation (INR > 10) – No Bleeding

• Give oral vitamin K 2.5–5 mg while holding warfarin. 4
• Expect the INR to fall toward therapeutic range within 24–48 h after oral vitamin K. 3

INR > 10 – Active Bleeding or Emergency Surgery

• Vitamin K must be given concurrently with fresh‑frozen plasma (FFP) or 4‑factor prothrombin complex concentrate (4F‑PCC) because vitamin K alone has a delayed onset (4–6 h IV, 18–24 h oral). 4

High‑Dose Vitamin K Avoidance

• Do not administer vitamin K > 5 mg for asymptomatic INR elevation; high‑dose vitamin K can create warfarin resistance and impede re‑anticoagulation after procedures. 4

Administration Route Considerations

• Subcutaneous vitamin K is discouraged due to unpredictable and delayed correction of INR. 3

Warfarin Restart Strategy

• After an INR elevation, restart warfarin at a reduced dose (10–20 % lower weekly dose) rather than the previous dose to avoid recurrent supratherapeutic INR. 3

Mechanical Heart Valves (Special Population)

• For INR 5–10 without bleeding, withhold warfarin but do not give routine vitamin K to prevent a hyper‑coagulable nadir. 4
• In emergency surgery, give low‑dose oral vitamin K 1–2 mg together with FFP or 4F‑PCC; higher vitamin K doses are discouraged to facilitate post‑procedure therapeutic INR achievement. 4

Pre‑operative Management

• Elective surgery performed when INR > 1.5 one day prior: do not give routine vitamin K (Conditional recommendation, Very Low Certainty). 5
• Urgent high‑bleeding‑risk procedures: if INR > 5, consider oral vitamin K 3–5 mg to obtain correction within 24 h. 6

Monitoring Strategy

• Re‑check INR 24–48 h after any warfarin hold or vitamin K dose. 3
• Patients with ≥2 bleeding‑risk factors should have daily INR monitoring until the value falls below 3.0. 3
• Actively investigate reversible causes of INR elevation (new interacting medications, acute illness, dietary changes, alcohol intake). 3